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NeOBJECTIVES This study sought to compare the inﬂuence of the extent of multidetector computed tomography (MDCT)
area oversizing on the incidence of paravalvular aortic regurgitation (PAR) between the Sapien 3 and the Sapien XT
transcatheter heart valve (THV) to deﬁne a new MDCT sizing guideline suitable for the Sapien 3 platform.
BACKGROUND The inverse relationship of PAR occurrence and oversizing has been demonstrated for the Sapien XT but
the incidence of PAR with comparable oversizing with the Sapien 3 is not known.
METHODS Sixty-one prospectively enrolled patients who underwent transcatheter aortic valve replacement with the
Sapien 3 THV were compared with 92 patients who underwent transcatheter aortic valve replacement with the Sapien XT
THV. Patients were categorized depending on the degree of MDCT area oversizing percentage: undersizing (below 0%),
0% to 5%, 5% to 10%, and above 10%. The primary endpoint was mild or greater PAR on transthoracic echocardiography.
RESULTS Mild or greater PAR was present in 19.7% of patients (12 of 61) in the Sapien 3 group and in 54.3% of patients
(50 of 92) in the Sapien XT group (p < 0.01). The Sapien 3 group, compared with the Sapien XT group, consistently
demonstrated signiﬁcantly lower rates of mild or greater PAR except for oversizing >10% (p for interaction ¼ 0.54).
Moderate or severe PAR rates were also lower in the Sapien 3 group than in the Sapien XT group (3.3% vs. 13.0%, p ¼
0.04). In the Sapien 3 group, a MDCT area oversizing percentage value of #4.17% was identiﬁed as the optimal cutoff
value to discriminate patients with or without mild or greater PAR.
CONCLUSIONS Our retrospective analysis suggests that the Sapien 3 THV displays signiﬁcantly lower rates of PAR than
does the Sapien XT THV. A lesser degree of MDCT area oversizing may be employed for this new balloon-expandable
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463AB BR E V I A T I O N S
AND ACRONYM S
AUC = area under the curve
CI = conﬁdence interval
MDCT = multidetector
computed tomography
OR = odds ratio
PAR = paravalvular aortic
regurgitation
TAVR = transcatheter aortic
valve replacement
THV = transcatheter heart
valve(s)T ranscatheter aortic valve replacement(TAVR) has become an effective treatmentof severe aortic stenosis in patients consid-
ered to be of high perioperative mortality risk (1)
and those deemed to be high risk for surgery (2,3).
Despite continuous procedural reﬁnements, para-
valvular aortic regurgitation (PAR) and aortic root
injury remain important limitations in the widening
of its application to lower-risk patients (4,5). Appro-
priate sizing of the transcatheter heart valve (THV)
is critically important to minimize the incidence of
PAR. Moderate to severe PAR has been shown
to be an independent predictor of mortality (3,5).
Multidetector computed tomography (MDCT) has
recently been shown to be predictive of PAR owing
to its 3-dimensional capabilities and better apprecia-
tion of the noncircular annular geometry (6,7).
Importantly, integration of a MDCT annulus area
sizing algorithm reduced PAR in patients receiving
Sapien XT THV in a prospective multicenter ap-
proach (8). However, it is well accepted that a single
sizing algorithm for all valve platforms is not accept-
able and that sizing needs to be reﬁned depending
on valve design.
The Sapien 3 THV has been recently introduced
with an external sealing cuff and improved delivery
catheter with the goal of reducing PAR by means of its
enhanced paravalvular sealing and more accurate
positioning. In the ﬁrst case series, an MDCT sizing
algorithm designed for a previous valve generation
was used (9); however, it is unclear whether this is
appropriate. We herein sought to compare the in-
cidences of PAR with comparable MDCT area over-
sizing between the Sapien 3 and the Sapien XT
THV and to serve as an exploratory analysis to
help deﬁne a new MDCT sizing guideline for the
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STUDY POPULATION. Patients enrolled in
the prospective safety and performance study
of the Edwards Sapien 3 THV were considered
for this analysis. The SAPIEN 3 THV study
was a nonrandomized, prospective multi-
center study that consisted of 150 patients
with severe symptomatic calciﬁc aortic valve
stenosis (intermediate or high operative risk)
at 15 participating centers across Canada,
France, Germany, Italy, and the United
Kingdom. Patients in whom the THV was
implanted too high or low were excluded
from the current study (6,7). Patients who did not
undergo pre-TAVR MDCT or post-TAVR echocardiog-
raphy, patients with nondiagnostic image quality on
pre-TAVR MDCT, and patients without systolic image
data on pre-TAVR MDCT were also excluded. At the
time of this analysis, 135 of the anticipated 150 pa-
tients had been enrolled into the SAPIEN 3 THV study
of whom 61 patients met the inclusion criteria for this
analysis from January 1, 2013 to September 30, 2013
(Figure 1). For comparison, an historical cohort of 92
patients who underwent TAVR with the Sapien XT
THV between January 1, 2011 and June 30, 2012 was
investigated. These 92 patients were derived from our
previous study to analyze MDCT annular dimension
for the prediction of PAR (6). An experienced inter-
ventional cardiologist (J.W.) who was unaware of the
grade of PAR, THV size, and MDCT annular dimension
reviewed the THV position on pre- and post-implant
aortic root angiography. Written consent was ob-
tained from all patients.
THV SIZE SELECTION. At each participating center,
the THV size selection was at the discretion of the
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FIGURE 1 Study Flowchart
The ﬂowchart provides information about the included and excluded patients in the Sapien 3 and Sapien XT THV groups. MDCT ¼multidetector
computed tomography; TAVR ¼ transcatheter aortic valve replacement; THV ¼ transcatheter heart valve; TTE ¼ transthoracic
echocardiography.
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464recommendation provided by the core laboratory
(J.L.), transesophageal echocardiography annular
measurements, and vendor speciﬁcations.
MDCT IMAGE ACQUISITION. MDCT protocols were
applied according to each center’s standard practice.
Scans were performed with electrocardiography-
synchronized data acquisition with a requirement
for systolic phase imaging.
MDCT IMAGE ANALYSIS. All MDCT examinations
were reviewed by 2 experienced cardiac CT readers
(J.L. and T.H.Y.) at the MDCT core lab of the SAPIEN 3
THV study (St. Paul Hospital, Vancouver, British
Columbia, Canada). A double-oblique transverse view
at transecting through the basal hinge points of
3 aortic cusps was obtained, deﬁning the aortic
annulus plane (10). Planimetry of the annulus con-
tours yielded area, long diameter, short diameter,
and circumference. Annulus area was measured by
manually tracking the luminal contours on double-
oblique transverse plane. Annular measurements
were performed in systole at 25% or 35% of the RR
interval. When systolic imaging data was not avail-
able, systolic annulus dimensions were modeled
based on the ﬁndings of a previous study (11). Aorticannular eccentricity was calculated as: 1 – short
diameter/long diameter. The annulus was separately
analyzed for calciﬁcation. If present, the distribution
of calciﬁcation and extension into the left ventricular
outﬂow tract were also assessed in a semiquantitative
fashion as follows: mild, 1 nodule of calcium
extending <5 mm in any direction and covering <10%
of the perimeter of the annulus; moderate, 2 nodules
of calciﬁcation or 1 extending >5 mm in any direction
or covering >10% of the perimeter of the annulus;
severe, multiple nodules of calciﬁcation of single
focus extending >1 cm in length or covering >20% of
the perimeter of the annulus (12). All image data were
analyzed ofﬂine on a 3-dimensional workstation (AW
4.4, GE Healthcare, Waukesha, Wisconsin, or Intui-
tion, Terarecon, Foster City, California). By conven-
tion, all measurements were repeated 2 times by 2
cardiac CT readers with the ﬁnal measurements rep-
resenting the mean of both measurements.
ECHOCARDIOGRAPHIC ASSESSMENT. Pre-TAVR trans-
esophageal echocardiography and post-TAVR trans-
thoracic echocardiography were performed by highly
experienced echocardiographers at each participating
center. Post-TAVR echocardiography was performed
at 30 days after TAVR in the Sapien 3 group and at
FIGURE 2 Sapien 3 THV
The nominal external valve area, diameter, and perimeter are shown for the Sapien 3 transcatheter heart valve (THV).
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465discharge in the Sapien XT group. Echocardiogra-
phies performed within a range of post-TAVR 21 to
100 days in the Sapien XT group were also analyzed.
Post-TAVR studies were interpreted by core labs
blinded to the pre-TAVR annulus dimensions and
implanted THV size (for the Sapien 3 THV, C5
Cleveland Clinic, Cleveland, Ohio; for the Sapien XT
group, St. Paul Hospital). PAR was graded in the
same fashion as none, mild, moderate, and severe
according to the Valve Academic Research Con-
sortium 2 criteria (13).
DEGREE OF AREA OVERSIZING OR UNDERSIZING.
The nominal external valve area of an expanded Sa-
pien 3 THV is 328 mm2 (20-mm device), 409 mm2
(23-mm), 519 mm2 (26-mm), 649 mm2 (29-mm) ac-
cording to the manufacturer (Figure 2) as compared to
the Sapien XT THV with expanded areas of 314 mm2,
415 mm2, 531 mm2, and 661 mm2, respectively. A THV
was considered oversized when the THV nominal area
was greater than the systolic MDCT annular area was.
The percentage of oversizing (positive percentage) or
undersizing (negative percentage) was calculated
using the following formula: % oversizing ¼ (THV
nominal area/MDCT annular area – 1)  100.
STUDY ENDPOINTS. The primary endpoint was the
presence of mild or greater PAR. The secondary
endpoint was the presence of moderate or severe
PAR.
STATISTICAL ANALYSIS. The Student t test and the
Mann-Whitney U test were used for comparison of
continuous variables with normal or skewed distri-
bution, when appropriate. The Fisher exact test was
used to test for signiﬁcant differences between cate-
gorical variables. A priori, we categorized patientsdepending on the degree of MDCT area oversizing
percentage in the following cohorts: undersizing
(below 0%); 0% to 5%; 5% to 10%; and above 10%. The
interactions among THV type implanted, MDCT area
oversizing category, and rates of mild or greater PAR
were analyzed using the multivariable model with
addition of an interaction term of THV type  MDCT
area oversizing variables. A receiver-operating char-
acteristics curve analysis was performed to evaluate
the discriminative abilities of MDCT annular mea-
surements in predicting mild or greater PAR and to
identify the cutoff level for MDCT area oversizing
percentage in predicting mild or greater PAR. The
relationship of PAR, annulus calciﬁcation, or area
oversizing percentage was investigated by univariate
or multivariate logistic regression analysis. A p
value #0.05 was considered statistically signiﬁcant.
All statistical analyses were performed by using SPSS
(version 18.0, SPSS Inc., Chicago, Illinois) software.
RESULTS
PATIENT POPULATION. Baseline clinical character-
istics are shown in Table 1. Except for patient age,
there was no signiﬁcant difference in regard to clin-
ical or demographic baseline characteristics.
ANNULAR ASSESSMENT AND PROCEDURE. Annular
dimensions and procedural characteristics are pre-
sented in Table 2. Average oversizing was 6.5  11.0%
in the Sapien 3 group (range –15.2 to 32.7%) and
4.7  17.2% in the Sapien XT group (range –21.7 to
59.6%) with no signiﬁcant different between groups
(p ¼ 0.42). Undersizing was present in 18 patients
(29.5%) in the Sapien 3 group and in 41 patients
(44.6%) in the Sapien XT group (p ¼ 0.07). MDCT area
TABLE 1 Baseline Clinical Characteristics
Sapien
3 Group
(n ¼ 61)
Sapien XT
Group
(n ¼ 92) p Value
Age, yrs 84.6  5.2 81.1  8.5 <0.01
Male 25 (41.0) 48 (52.2) 0.19
Height, cm 164.4  10.1 164.9  25.0 0.89
Weight, kg 74.9  17.7 77.4  21.9 0.50
Body mass index, kg/m2 27.7  6.3 26.9  6.1 0.46
Diabetes 19 (31.1) 25 (27.2) 0.72
Hypertension 53 (86.9) 71 (77.2) 0.15
COPD 16 (26.2) 20 (21.7) 0.56
Atrial ﬁbrillation 27 (44.3) 34 (37.0) 0.40
Peripheral vascular disease 11 (18.0) 17 (18.5) 1.00
Smoking history 24 (39.3) 31 (33.7) 0.50
Previous cerebrovascular
accident
12 (19.7) 12 (13.0) 0.36
Previous myocardial infarction 7 (11.5) 15 (16.3) 0.49
Previous open heart surgery 12 (19.7) 26 (28.3) 0.26
Previous permanent pacemaker 10 (16.4) 8 (8.7) 0.20
GFR, ml/min 58.1  26.7 57.4  20.6 0.87
STS PROM, % 7.2  4.1 6.2  2.9 0.10
Values are mean  SD or n (%).
COPD ¼ chronic obstructive pulmonary disease; GFR ¼ glomerular ﬁltration
rate; STS PROM ¼ Society of Thoracic Surgeons predicted risk of mortality.
TABLE 2 Annular Assessment and Procedural Characteristics
Sapien 3 Group
(n ¼ 61)
Sapien XT Group
(n ¼ 92) p Value
Pre-TAVR aortic regurgitation <0.01
None/trivial 35 (57.4) 79 (85.2)
Mild 25 (41.0) 12 (13.0)
Moderate 1 (1.6) 1 (1.1)
Severe 0 (0.0) 0 (0.0)
Left ventricular ejection fraction, % 52.3  10.2 55.0  12.9 0.33
Mean gradient, mm Hg 44.7  14.3 43.9  17.3 0.77
Aortic valve area, cm2 0.64  0.19 0.69  0.17 0.18
MDCT short-axis diameter, mm 22.5  2.4 21.0  2.4 <0.01
MDCT long-axis diameter, mm 26.6  2.2 26.8  2.9 0.71
MDCT mean-diameter, mm 24.5  2.1 23.9  2.4 0.10
MDCT annular area, cm2 485.8  77.5 467.9  90.6 0.21
MDCT annular circumference, mm 80.7  6.3 78.5  8.9 0.08
MDCT annular eccentricity 0.15  0.07 0.21  0.08 <0.01
Labeled prosthesis size <0.01
20-mm 0 (0.0) 2 (2.2)
23-mm 16 (26.2) 41 (44.6)
26-mm 33 (54.1) 45 (48.9)
29-mm 12 (19.7) 4 (4.3)
MDCT nominal area oversizing, % 6.5  11.0 4.7  17.2 0.42
Post-dilation 2 (3.3) 9 (9.8) 0.20
Access type 0.10
Transfemoral 43 (70.5) 65 (70.7)
Transapical 15 (24.6) 27 (29.3)
Transthoracic 3 (4.9) 0 (0.0)
Values are n (%) or mean  SD.
MDCT ¼ multidetector computed tomography; TAVR ¼ transcatheter aortic valve replacement.
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466oversizing percentage of 0% to 5%, 5% to 10%, and
above 10% was present in 10 patients (16.4%), 15
(24.6%), and 18 (29.5%) in the Sapien 3 cohort and
in 10 (10.9%), 11 (12.0%), and 30 (32.6%) in the Sapien
XT cohort.
PAR. Post-TAVR transthoracic echocardiography data
is summarized in Table 3. Overall, mild, or greater
PAR was present in 19.7% of patients (12 of 61) in the
Sapien 3 group and in 54.3% of patients (50 of 92) in
the Sapien XT group (p < 0.01). Figure 3 illustrates the
rates of mild or greater PAR stratiﬁed by the extent of
MDCT area oversizing percentage. The Sapien 3 group
demonstrated signiﬁcantly lower rates of mild or
greater PAR compared with the Sapien XT group
except for the subgroup with area oversizing above
10% (p for interaction ¼ 0.54). In the Sapien 3 group,
patients with 0% to 5% oversizing exhibited numeri-
cally higher rates of mild or greater PAR without
statistical signiﬁcance compared with patients with
5% to 10% oversizing (30.3% vs. 13.3%, p ¼ 0.36).
Similarly, patients with undersizing exhibited slightly
higher rates of mild or greater PAR compared with
patients with oversizing (27.8% vs. 16.3%, p ¼ 0.31).
We found a declining trend in the rates of mild or
greater PAR in patients in the Sapien 3 group with
increasing area oversizing, whereas the Sapien XT
group provided little change (Figure 4). With regard to
moderate or severe PAR, Sapien 3 patients demon-
strated lower PAR rates than did Sapien XT patients
throughout all subgroups: undersizing (0.0% vs.
19.5%, p ¼ 0.04); area oversizing between 0% and 5%
(10.0% vs. 20.0%, p ¼ 0.53); and area oversizing be-
tween 5% and 10% (6.7% vs. 18.2%, p ¼ 0.36). No
patients with either Sapien 3 or Sapien XT exhibited
moderate or severe PAR when MDCT area oversizing
percentage exceeded 10%. A total of 96 Sapien 3
subjects, encompassing 61 patients with direct sys-
tolic measurements as well as 35 patients with
modeled data, also manifested similar ﬁndings in the
rates of mild or greater and moderate or greater PAR
when compared with all Sapien XT subjects (20.8%
vs. 54.3%, p < 0.01 and 3.1% vs. 13.0%, p ¼ 0.02)
(Figure 5). Likewise, the incidences of mild or greater
and moderate or greater PAR were lower in the Sapien
3 patients (n ¼ 61), which was consistent when
compared with the Sapien XT patients with follow-up
echocardiography conducted from 21 days to 100 days
(n ¼ 61) (19.7% vs. 47.7%, p < 0.01 and 3.3% vs. 12.3%,
p ¼ 0.06). Representative case examples are pre-
sented in Figure 6.
AREA UNDER THE CURVE. Sapien 3 THV nominal
area and MDCT annular area provided weak predic-
tion of mild or greater PAR (area under the curve
TABLE 3 Post-TAVR Outcomes
Sapien 3 Group
(n ¼ 61)
Sapien XT Group
(n ¼ 92) p Value
Post-TAVR PAR
None/trivial 49 (80.3) 42 (45.7) <0.01
Mild 10 (16.4) 38 (41.3) <0.01
Moderate 2 (3.3) 12 (13.0) 0.04
Severe 0 (0.0) 0 (0.0) 1.00
Mild or greater 12 (19.7) 50 (54.3) <0.01
Mean gradient, mm Hg 10.9  5.5 11.0  4.4 0.88
Aortic valve area, cm2 1.6  0.5 1.5 0.3 0.31
Procedural mortality 0 (0.0) 0 (0.0) 1.00
30-day mortality 0 (0.0) 2 (2.2) 0.24
Annular rupture 0 (0.0) 0 (0.0) 1.00
Device embolization 0 (0.0) 0 (0.0) 1.00
Procedural myocardial infarction 0 (0.0) 1 (1.1) 0.49
Values are n (%) or mean  SD.
PAR ¼ paravalvular aortic regurgitation; TAVR ¼ transcatheter aortic valve replacement.
FIGURE 3 Rates of Mild or Greater PAR According to MDCT Nominal Area Oversizing
Group in All Study Populations
The numbers in the columns denote the absolute numbers and rates of mild or greater
paravalvular aortic regurgitation (PAR). CI ¼ conﬁdence interval; MDCT ¼ multidetector
computed tomography; OR ¼ odds ratio.
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467[AUC]: 0.67, 95% conﬁdence interval [CI]: 0.54 to
0.78, p ¼ 0.04). The difference between the Sapien 3
THV nominal diameter and MDCT annular mean
diameter (AUC: 0.54, 95% CI: 0.40 to 0.67, p ¼ 0.68),
the Sapien 3 THV nominal circumference and MDCT
annular circumference (AUC: 0.58, 98% CI: 0.44 to
0.71, p ¼ 0.44) did not show signiﬁcant predictive
value. In contrast, the relationship between the Sa-
pien XT THV size and MDCT annular size ([area: AUC:
0.73, 95% CI: 0.63 to 0.82, p < 0.01], [mean diameter:
AUC: 0.74, 95% CI: 0.64 to 0.83, p < 0.01], circum-
ference: AUC: 0.73, 95% CI: 0.63 to 0.81, p < 0.01])
had moderate predictive value.
THE RELATIONSHIP BETWEEN PAR AND ANNULUS
CALCIFICATION. Mild or greater PAR occurred more
frequently in patients with moderate or severe
annulus calciﬁcation than in patients without mod-
erate or severe annulus calciﬁcation in the Sapien 3
group (odds ratio [OR]: 7.80, 95% CI: 1.95 to 31.22,
p < 0.01), whereas this difference could not be found
in the Sapien XT group (Table 4). Similarly, moderate
or severe PAR was more common in patients having
moderate or severe annulus calciﬁcation (11.1% vs.
0.0%, p ¼ 0.08) in the Sapien 3 group. In the multi-
variate logistic regression analysis, moderate or se-
vere annulus calciﬁcation (OR: 10.0, 95% CI: 1.22 to
81.48, p ¼ 0.03) was found to be signiﬁcant and in-
dependent predictors of mild or greater PAR after
adjusting for age, sex, annulus eccentricity, and
MDCT area oversizing percentage in the Sapien 3
patients.
THE IMPACT OF MINIMAL AREA OVERSIZING ON
PAR. In the Sapien 3 group, an MDCT area oversizing
percentage value of #4.17% was identiﬁed as the
optimal cutoff value to discriminate patients with or
without mild or greater PAR that provided a sensi-
tivity of 66.7%, a speciﬁcity of 65.3%, a positive pre-
dictive value of 32.0%, and a negative predictive
value of 88.9%. We then dichotomized the area
oversizing value at a practical value of 5.0%. For pa-
tients with area oversizing below 5.0%, the rate of
mild or greater PAR was 25.0% (7 of 28) versus 9.1%
(3 of 33) (OR: 2.90, 95% CI: 0.77 to 10.95, p ¼ 0.11)
when the area oversizing was above 5.0%. In the
Sapien XT group, an optimal MDCT area oversizing
cutoff value to predict mild or greater PAR was 7.27%
(sensitivity: 84.0%, speciﬁcity: 61.9%, positive pre-
dictive value: 72.4%, negative predictive value:
76.5%). In the Sapien 3 subgroup (n ¼ 33) whose area
oversizing was above 5%, if 2 patients with moderate
or severe annulus calciﬁcation and mild or greater
PAR were excluded from total 4 patients who hadmild or greater PAR, only 2 patients (of 31 patients,
6.5%) would have had mild or greater PAR.DISCUSSION
In our comparison of the incidence and severity of
PAR with MDCT nominal area oversizing or under-
sizing after TAVR with the Sapien 3 or Sapien XT THV,
the Sapien 3 THV appears to tolerate a lesser degree of
area oversizing. Our current results demonstrate the
following. 1) The Sapien 3 THV, compared with the
FIGURE 4 Rates of Mild or Greater PAR Stratiﬁed by Extent of MDCT Nominal Area
Oversizing in All Study Populations
Each subgroup on the x-axis indicates all patients with area oversizing below each criterion
and inclusive of undersizing. *All p values between the Sapien 3 group and Sapien XT group
were <0.02 at all area oversizing criteria. Abbreviations as in Figures 1 and 3.
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468Sapien XT, appears to exhibit signiﬁcantly lower rates
of mild or greater PAR when all minimal area over-
sizing criteria are applied. 2) MDCT annular size
measurements provide weaker prediction of mild or
greater PAR after the Sapien 3 THV implantation than
the Sapien XT THV implantation. 3) Annulus calcium
plays a role in the occurrence of mild or greater PAR
after the Sapien 3 THV implantation. 4) A lesser de-
gree of MDCT area oversizing might be employed forf Mild or Greater PAR According to MDCT Nominal Area Oversizing
ith Systolic MDCT Measurements
columns denote the absolute numbers and rates of mild or greater
s in Figures 1 and 3.this new balloon-expandable THV than the currently
recommended value for the Sapien XT THV.
PAR continues to be an important complication
after TAVR because the prognostic implications are
not negligible (3,5). Even mild PAR has been associ-
ated with a worse prognosis (3). A meta-analysis of 45
studies also demonstrated that patients with mild
PAR had a 1.8 higher risk of 1-year mortality than did
those without this complication (14).
DECREASED PAR WITH THE SAPIEN 3 THV.
Two main causes of PAR with balloon-expandable
prostheses are felt to be implantation of a THV that
is relatively smaller than aortic annulus (undersizing)
or positioning the device too high or too low (14,15).
In the present study, the rate of mild or greater PAR
was signiﬁcantly lower in the Sapien 3 group than in
the Sapien XT group except for patients with area
oversizing above 10% where both groups had a low
incidence of PAR. Possible reasons for this lower PAR
rate are the outer polyethylene terephthalate sealing
cuff, which enhances paravalvular sealing and more
accurate positioning. The enhanced paravalvular
sealing with the Sapien 3 THV was especially useful in
patients with area oversizing below 10%.
PREDICTION OF PAR. In the Sapien 3 group, AUC of
MDCT annular measurements were not as high as
those in the Sapien XT group. Two possible explana-
tions for the discriminatory value of these MDCT
measurements are as follow: 1) the differences be-
tween oversizing percentage in patients without PAR
and undersizing percentage in patients with PAR in
the Sapien 3 group have become smaller than those in
the Sapien XT group, possibly due to increased
awareness of appropriate annular oversizing and the
integration of a MDCT-based THV sizing algorithm;
and 2) the occurrence of mild or greater PAR in the
Sapien 3 group can be affected by factors other than
THV undersizing or inappropriate THV positioning
(i.e., annulus calciﬁcation).
ANNULUS CALCIFICATION AS A POTENTIAL CAUSE
OF PAR. Moderate or severe annulus calciﬁcation
was associated with mild or greater PAR in the Sapien
3 group. This ﬁnding is in line with previous studies
demonstrating that annulus calciﬁcation is a risk
factor for PAR in addition to THV undersizing and
malpositioning (16). Therefore, it is important to un-
derstand that appropriate annular oversizing,
although crucial, is not the only factor that affects the
development of PAR after TAVR even with the Sapien
3 THV. The presence of anatomical modiﬁers such as
annulus calciﬁcation should be considered particu-
larly when the degree of annulus area oversizing is
FIGURE 6 Pre- and Post-TAVR Imaging in A Patient in the Sapien 3 Group With No Signiﬁcant PAR and in A Patient in the Sapien XT
Group With Moderate PAR
(A) Double oblique transverse reformat of the annulus on MDCT with an area of 480 mm2 in an 82-year-old female patient in the Sapien 3
group who had 8.1% area oversizing with the use of the 26-mm Sapien 3 THV. (B) The parasternal long-axis 2-dimensional echocardiography
showing no signiﬁcant PAR. (C) Double oblique transverse reformat of the annulus on MDCT with an area of 490 mm2 in a 69-year-old male
patient in the Sapien XT group who had 8.4% area oversizing with the use of 26-mm Sapien XT. (D) The parasternal long-axis 2-dimensional
echocardiography showing moderate degree of PAR. Abbreviations as in Figures 1 and 3.
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469modest (below 10%). Interestingly, the impact of
annular calciﬁcation appears to be greater for the
Sapien 3 than for the Sapien XT. This most likely re-
ﬂects that the Sapien XT is more profoundly affected
by modest oversizing, thereby muting the potential
impact of annular calciﬁcation.
THE OPTIMAL DEGREE OF AREA OVERSIZING IN THE
SAPIEN 3 THV. It has been established that signiﬁ-
cant oversizing of a THV can minimize the risk of
signiﬁcant PAR; however, excessive oversizing
comes at the expense of increasing the potential risk
of aortic root rupture (12), coronary obstruction (17),
periaortic hematoma, atrioventricular block, or ven-
tricular septal rupture, whereas signiﬁcant THV
undersizing will increase the risk of signiﬁcant PAR
(6) and, less frequently, prosthesis embolization (18).
Furthermore, treating signiﬁcant PAR due to THV
undersizing is challenging (19), so optimal sizing and
appropriate selection of THV are crucial to reducesigniﬁcant PAR and mechanical aortic root injuries. In
our previous study, patients who underwent TAVR
with the integration of MDCT-based area sizing algo-
rithm had a signiﬁcant reduction in greater than mild
PAR (5.3%) as compared with those who underwent
exclusively 2-dimensional echocardiography-based
sizing (12.8%) (8). However, this positive ﬁnding was
based on the annulus area sizing algorithm of the
Sapien XT THV. Therefore, a new area sizing algo-
rithm that is suitable for the Sapien 3 THV would be
desirable.
In the current study, the optimal cutoff value of
MDCT area oversizing for the prediction of mild or
greater PAR was lower in the Sapien 3 group than in
the Sapien XT group and the currently recom-
mended area oversizing thresholds of 5% to 15%. In
addition, patients with 0% to 5% oversizing had only
numerically higher rates of mild or greater PAR
without statistical signiﬁcance when compared with
patients with 5% to 10% oversizing. These ﬁndings
TABLE 4 Relationship Between Moderate or Severe Annulus Calciﬁcation
and Mild or Greater PAR
Present* Absent* p Value
Sapien 3
All patients 8/18 (44.4) 4/43 (9.3) <0.01
Oversizing <0% 3/8 (37.5) 2/10 (20.0) 0.61
Oversizing between 0% and 10% 5/8 (62.5) 0/17 (0.0) <0.01
Oversizing >10% 0/2 (0.0) 2/16 (12.5) 1.00
Sapien XT
All patients 5/7 (71.4) 45/85 (52.9) 0.45
Oversizing <0% 4/5 (80.0) 25/36 (69.4) 1.00
Oversizing between 0% and 10% 0/0 15/21 (71.4) NA
Oversizing >10% 1/2 (50.0) 5/28 (17.9) 0.37
Values are n/N (%). *Moderate or severe annulus calcium present or absent.
PAR ¼ paravalvular aortic regurgitation.
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470suggest that the optimal goal of annulus area over-
sizing with the Sapien 3 THV may be decreased
down to between 1% and 5%. This minimal area
oversizing may confer a great advantage of a lower
risk of annulus injury without an increased risk of
PAR. In addition, the more modest burden of PAR in
the setting of mild undersizing of the annulus noted
with the Sapien 3 THV may prove to be extremely
helpful for borderline annular geometry where the
operator has been historically faced with the difﬁcult
decision of undersizing or extreme annular oversiz-
ing with a larger THV leaving the patient at an
elevated risk of moderate PAR or annular injury. We
have previously described a strategy of balloon
underﬁlling with the Sapien XT to help optimize the
degree of annular oversizing and mitigate the risk of
annular rupture (20). The role of underﬁlling with
the Sapien 3 is not known, although there are con-
cerns about employing this strategy owing to
different design features that may result in earlier
valve degeneration.
STUDY LIMITATIONS. The timing of post-TAVR
echocardiography was somewhat different between
the 2 groups. Although the prevalence and degree of
PAR can diminish as time passes, it may be reason-
able to assume that the time gap (20 days) was not
great enough to result in substantive reduction or
increase in PAR. In addition, we found similar
ﬁndings in the rates of mild or greater andmoderate or greater PAR between the Sapien 3 pa-
tients and the Sapien XT patients with echocardio-
graphic assessment at a comparable time frame
(post-TAVR 21 to 100 days).
Whereas all MDCT scans were read in a single core
lab, post-TAVR echocardiography was read at 2
different core labs. Grading of PAR may be heteroge-
neous across sites. However, all sites’ reads were
performed by Level 3 echocardiographers with sig-
niﬁcant experience in TAVR and graded according to
a standard deﬁnition.
The number of patients in both groups was small
and thus the results, particularly the comparison be-
tween the 2 THV should be taken cautiously and as
grounding for future investigation.
In addition, the baseline annulus dimensions were
different and therefore larger THV were implanted in
the Sapien 3 group. But the degree of MDCT nominal
area oversizing was not different, so we do not think
that such a baseline difference could have an effect
on ﬁnal results.
Finally, the Sapien XT group consisted of patients
who underwent TAVR a year earlier than the Sapien 3
group. A learning effect, which may have led to
improved outcomes in the Sapien 3 cohort, could be
postulated. However, highly experienced operators in
high-volume centers performed >200 TAVR pro-
cedures prior to implanting the Sapien XT.CONCLUSIONS
In our exploratory comparative analysis, the Sapien
3 THV appears to display signiﬁcantly lower rates
of PAR than the Sapien XT THV does. A lesser
degree of MDCT area oversizing appears appro-
priate for this new balloon-expandable THV,
thereby potentially reducing the potential risk of
annular rupture; however, further studies evalu-
ating this new MDCT sizing guideline for the Sapien
3 THV are needed.
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